Kornimate/medical-research-clean huggingface dataset:
nutritional impact of moringa oleifera leaf supplementation in mothers and children

Conditions: Malnutrition; Wasting; Growth Failure

Summary: studies to date on the effects of moringa oleifera in diabetes and anemia and animal studies that examine the utility of moringa for increased milk and litter yield are of small scale, however high-quality large-scale placebo or case-controlled clinical trials to define the impact on infants of moringa leaf powder consumption by breastfeeding mothers are lacking. moringa has a traditional and agricultural history of use as a galactagogue; despite this and its incorporation into products such as mother's milk tea© and placement on nih lactmed lactation database, this property has not been studied in large clinical trials nor in populations dependent on breastmilk such as in kisumu, kenya. this study will improve and add to existing knowledge of moringa's effect on human breastmilk and will provide novel information on the effect of moringa supplementation to lactating mothers on their infant's intestinal inflammation and health. after trial registration, the study was modified to include infant follow up to 18 months for some measures and the children's groups were removed. although the study was modified to an 18 month follow up, the data were not able to be collected. further understanding of the acceptability of moringa leaf in a staple food of porridge and more the effect of moringa supplementation on infant and childhood growth, nutrition, and intestinal and systemic inflammation may translate in the future to the cultivation of moringa at the community or household level as an effective resource for the improvement of childhood undernutrition.


Eligibility criteria:
inclusion criteria: * lactating women at least 18 years of age and their exclusively breastfed infants within 14 days of delivery. * children 6-59 months of age who eat food exclusion criteria: * regular maternal consumption of moringa * receipt and consumption of food supplementation program * inability to feed orally or refusal to eat moringa or placebo porridge * for infants, prematurity (\<36 weeks gestational age) * for infants, significant congenital disease * for infants, inability to feed orally

Keywords: moringa oleifera supplementation
effect of fermented soybean (fsb) supplementation on gas-troesophageal reflux disease (gerd)

Conditions: Gastro Esophageal Reflux

Summary: gastroesophageal reflux disease (gerd) is a prevalent chronic condition affecting the well-being of both adults and children in general medical practice. research on the effects of fermented soy-bean (fsb) supplementation in managing gerd is relatively new, with limited studies available. existing research often lacks sufficient dosing regimens and study durations to differentiate be-tween transient placebo effects and sustained benefits. in this study, the beneficial effects of fsb supplementation were investigated in 50 voluntary participants. participants were required to take 1g of fsb supplement once daily for twelve weeks. gerd symptoms were evaluated using the reflux disease questionnaire (rdq), while inflammatory markers, including interleukin-4 (il-4), interleukin-6 (il-6), and interleukin-8 (il-8), were measured to assess inflammation. the quality of life in reflux and dyspepsia (qolrad) questionnaire was used to evaluate partici-pants' quality of life. results indicated that fsb supplementation significantly (p\<0.05) alleviated heartburn and regurgitation symptoms and reduced levels of il-4, il-6, and il-8, indicating a notable anti-inflammatory effect. additionally, significant (p\<0.05) improvements were observed in qolrad scores, particularly in vitality, emotional distress, and physical/social functioning. collectively, our findings support the use of fsb as an adjuvant approach in managing gerd, with notable improvements in patients' quality of life.


Eligibility criteria:
inclusion criteria: (1) experienced heartburn, acid reflux, regurgitation, or non-cardiac chest pain within the past three months; (2) aged 18 years or older; (3) demonstrated the ability to comprehend the study protocol and information provided by the investigators; and (4) provided in-formed consent. exclusion criteria: 1) use of medications related to gerd, such as acid inhibitors, antacids, prokinetics, gastric mucosal protectors, herbs, probiotics, or related preparations within the past two weeks; (2) a history of gastro-esophageal or duodenal surgery; (3) diagnosis of peptic ulcer, gastrointestinal bleeding, esophageal or gastric varices, or upper gi malignancies confirmed by endoscopy at tertiary hospitals; and (4) pregnancy or lactation

Keywords: gastroesophageal reflux disease (gerd) reflux disease questionnaire (rdq) inflammatory markers quality of life in reflux and dyspepsia (qolrad)
analysis of the impact of patent ductus arteriosus on brain function in preterm neonates: multimodal approach integrating eeg-nirs, ultrasound and clinical data

Conditions: Ductus Arteriosus, Patent

Summary: this project corresponds to the main field of research of the investigators's laboratory concerning analysis of cerebral electrometabolic and haemodynamic activity in neonates. in this context, the investigators have developed know-how and specific acquisition and analysis tools (2 patents and several publications), allowing them to apply this know-how in children with patent ductus arteriosus. patent ductus arteriosus after birth is characterized by shunting of a variable proportion of cardiac output towards the pulmonary circulation. the direct consequences of this shunting are: (i) overload of the pulmonary vasculature and left heart chambers, increasing the risk of left heart failure, haemorrhagic pulmonary oedema and late respiratory complications such as bronchopulmonary dysplasia; (ii) in contrast with the pulmonary circulation, other systemic organs are deprived of part of their normal perfusion and are subject to ischaemic hypoxia; the resulting neuronal hypoxia rapidly leads to metabolic and electrical dysfunction, the analysis of which constitutes one of the objectives of this project.


Eligibility criteria:
inclusion criteria: 1. group of children : * meeting the age criteria * having a ductus arteriosus persistence. 2. group of children : * meeting the age criteria * with persistent ductus arteriosus in the ultrasound examination * for which a cardiac or respiratory treatment has already been put in place. 3. normal group of children : * meeting the age criteria * without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological (etf , scanner, mri). exclusion criteria: -

Keywords: preterm neonates eeg-nirs
assessing the effects of omega-3 supplementation on some serum bdnf، follistatin، irisin levels in men with cad

Conditions: Cardiovascular Disease

Summary: the aim of this study is the comparison between the effects of supplementation with omega 3 or placebo for 8 weeks in serum level of bdnf، follistatin، irisin in patients with cardiovascular disease.

the aim of this study is the comparison between the effects of supplementation with omega 3 or placebo for 8 weeks in serum level of bdnf، follistatin، irisin in patients with cardiovascular disease. in this randomized, double-blind clinical trial, placebo-controlled, single-center, and phase two trials, 42men aged 45-65 years with coronary artery disease are enrolled in the study from tehran heart center. after signing informed consent all individuals complete a general information form , 24-hour food recall for 3 days will be taken from the participants at the beginning and the end of the study,. selected samples are randomly classified into 2 blocks of groups receiving supplement and placebo. the supplement group, will receive 4 g/day omega 3 fatty acid for 8 weeks and the placebo group will also receive placebo (containing 4 g of edible paraffin) (similar in terms of color, shape and size). patients are recommended to sustain their diets and medication dose (s) during the study and also advised to maintain a constant level of physical activity. blood samples will be collected after 8-12 hours fasting and anthropometric variables, biochemical parameters and physical activity before and after the trial will be measured.

Eligibility criteria:
inclusion criteria: * cardiovascular disease patients 45- 65 years old, * patients with ≥ 50% stenosis in at least one coronary angiogram demonstrated, * body mass index in the range 18.5- 35, * avoidance of dietary supplements, vitamins and herbal products at least 3 months before and throughout the intervention, * willingness to participation, exclusion criteria: * people who have used omega 3 supplements in last 3 months, * having chronic renal disease , * gi disease, * hepatobiliary diseases, * hematological disorders, * movement disorders, * myopathy , * hypo- or hyperthyroidism, * smokers

Keywords: atherosclerotic bdnf follistatin irisin
screening for postpartum depression and associated risk factors among women who deliver in four hospital in france during the covid-19 epidemic

Conditions: Postpartum Depression; Covid19; Prevalence; Social Distance

Summary: postpartum depression (ppd) represent around 15% of birth in developed countries. the context of the covid-19 epidemy represents a possible source of additional emotional distress. the objective of this study is to determine the screening prevalence and risk factors of postpartum depression, among women who deliver in fourth hospital in the north of france in the context of the covid epidemy.


Eligibility criteria:
inclusion criteria: * single baby delivery * alive new born child without admission in neonatal intensive care unit * french-speaking mother * mother older than 18 years old exclusion criteria: * patients who refuses the inclusion

Keywords: postpartum depression covid19 prevalence social distance
invasive intervention of local complications of acute pancreatitis

Conditions: Acute Pancreatitis

Summary: strategies for invasive intervention in acute pancreatitis include sequential or combined use of multiple drainage and debridement modalities. the more widely used is the step-up approach, which requires an individualized and multidisciplinary (internal medicine, interventional radiology, endoscopy, surgery, critical care medicine, and nutritionists) approach. the available evidence from randomized controlled studies is from highly selected subject populations, and it is unclear whether the results can be applied to complex clinical situations in real clinics, and the optimal strategy for drainage of peripancreatic lesions in different patients still needs to be evaluated in the real world. this study intends to establish a prospective single-center cohort for real-world analysis to collect comprehensive clinic information and clinical outcomes, to evaluate the effectiveness and safety of existing intervention strategies, especially the timing and modality of interventions, in real-world clinical practice, and to explore the key factors affecting patient prognosis.


Eligibility criteria:
inclusion criteria: * admission diagnosis of acute pancreatitis; * localized complications confirmed by imaging examinations; * voluntary participation in the study and signing of an informed consent form. exclusion criteria: * improved with conservative treatment without invasive interventions for local complications during hospitalization.
nutrition and outcomes of hematopoietic cell transplantation (hct)

Conditions: Allogeneic Stem Cell Transplant; Graft Versus Host Disease; Hematologic Malignancy; Stem Cell Transplant Complications

Summary: retrospective case-note review to determine if nutrition via the enteral compared to the parenteral route results in better outcomes after haematopoietic cell transplantation.

this is a retrospective case-note review of adults undergoing haematopoietic cell transplantation to treat a haematological malignancy who have been admitted to hammersmith hospital from 2000 to 2014. all patients receiving an allogeneic haematopoietic cell transplant from a matched sibling or identically matched unrelated donor will be included. we will record the route and assess the broad adequacy of nutritional intakes to determine if nutrition via the enteral compared to the parenteral route results in better outcomes after haematopoietic cell transplantation. our outcomes are graft versus host disease incidence and severity, transplant related (early) mortality and overall survival.

Eligibility criteria:
inclusion criteria: * patients undergoing their first hct for a hematologic malignancy * undergoing hct using a sibling or unrelated donor * undergoing hct infusion between january 2000 and december 2014 exclusion criteria: * hct using umbilical cord blood donors * hct using haploidentical donors

Keywords: enteral nutrition parenteral nutrition artificial nutrition support non-relapse mortality survival
early detection of covid-19 using breath analysis - feasibility study

Conditions: Covid19

Summary: early detection of covid-19 using breath analysis -feasibility study.

an interventional diagnostic prospective study study with risks and minimal constraints.

Eligibility criteria:
inclusion criteria: hospitalized group: * age 18 to 75 years at the time of consent * positive results for sars-cov-2 * capable of understanding written and/or spoken language * able to provide informed consent * was not treated with anti-viral drugs * not a pregnant woman healthy group: * healthy volunteers * age 18 to 75 years at the time of consent * no history of covid-19 * capable of understanding written and/or spoken language * able to provide informed consent * was not treated with anti-viral drugs * not a pregnant woman sexes eligible for study: all exclusion criteria: hospitalized group: * age under 18 years old * (anticipated) inability to complete breath sampling procedure due to e.g. hyper- or hypoventilation, respiratory failure or claustrophobia when wearing the sampling mask * persons under guardianship or deprived of liberty * patients with the following diseases: cancer, asthma, chronic respiratory disease healthy group: * age under 18 years old * history of covid-19 * persons under guardianship or deprived of liberty * subjects with the following diseases: cancer, asthma, chronic respiratory disease
a study of bgb-16673 compared to investigator's choice in participants with chronic lymphocytic leukemia or small lymphocytic lymphoma previously exposed to both bruton tyrosine kinase (btk) and b-cell leukemia/lymphoma 2 protein (bcl2) inhibitors

Conditions: CLL; Chronic Lymphocytic Leukemia

Summary: the purpose of this study is to investigate the efficacy and safety of bgb-16673 compared with investigator's choice (idelalisib plus rituximab \[for cll only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) previously exposed to both btk inhibitors (btki) and bcl2 inhibitors (bcl2i).

chronic lymphocytic leukemia is a type of blood cancer that affects people around the world. people with cll suffer from enlarged lymph nodes, spleen, or liver, or have symptoms like night sweats, weight loss and fever. they have shorter life expectancy compared to healthy people. there is an urgent need for new treatment to prolong life and control disease-related symptoms. in this study, participants with relapsed/refractory (r/r) cll who were previously exposed to a btki and a bcl2i will receive bgb-16673 or the investigator's choice of idelalisib plus rituximab (for cll only) or bendamustine plus rituximab or venetoclax plus rituximab retreatment. the main purpose of this study is to compare the length of time that participants live without their cll or sll worsening between those participants who receive bgb-16673 versus the investigator's choice of treatment (idelalisib plus rituximab or bendamustine plus rituximab, or venetoclax plus rituximab). approximately 250 participants will be included in this study around the world. participants will be randomly allocated to receive either bgb-16673 or the investigator's choice of treatment.

Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of cll or sll, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwcll) criteria. 2. previously received treatment for cll/sll with both a btki and a bcl2i. 3. participants with sll must have measurable disease by computer tomography (ct)/magnetic resonance imaging (mri) 4. eastern cooperative oncology group (ecog) score 0, 1, or 2 5. adequate liver function 6. adequate blood clotting function exclusion criteria: 1. known prolymphocytic leukemia or history of, or currently suspected, richter's transformation 2. prior autologous stem cell transplant or chimeric antigen receptor-t cell therapy in the last 3 months 3. known central nervous system involvement 4. prior exposure to any btk protein degraders 5. active fungal, bacterial and/or viral infection requiring parenteral systemic therapy 6. clinically significant cardiovascular disease note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: cll
the prevalence of erectile dysfunction (ed) and premature ejaculation (pe) in poland

Conditions: Erectile Dysfunction; Premature Ejaculation

Summary: the first large population-based study to evaluate erectile dysfunction (ed) and premature ejaculation (pe) in poland. the study objective is to assess the prevalence and bother of ed and pe in the representative group of male population of poland.


Eligibility criteria:
inclusion criteria: * age ≥18 * a sufficient level of education to understand study procedures and be able to communicate with site personnel exclusion criteria: • age \<18
comparing mouth rinses (and chewing gum) in regard to streptococcus mutans reduction

Conditions: Dental Caries

Summary: this study compared four mouth rinses/chews for their ability to reduce streptococcus mutans after usage. the four that were compared were chlorhexidine gluconate (0.12%), sodium fluoride (0.05%), paraffin wax chewing gum (sugar free), and deionized water. the paraffin wax chewing gum replaced the originally planned coconut oil and served as a placebo comparator.

the study was a randomized controlled clinical trial, unblinded. after obtaining consent and assent, respectively, and following review of medical history with regard to inclusion/exclusion criteria, if the participant met eligibility criteria, the participant was randomly assigned to one of four groups being studied: chlorhexidine gluconate (0.12%), sodium fluoride (0.05%), paraffin wax chewing gum (sugar-free) or deionized water with a randomization ratio of 1:1:1:1. a pre rinse/chew salivary sample was obtained by having the participant spit into a sterile test tube. the participant then either rinsed with 10ml of the assigned rinse for a timed 30 seconds and expectorated, or chewed paraffin wax chewing gum for 2 minutes. a post rinse/chew salivary sample was taken similarly to the pre rinse/chew sample. the samples were transported to a microbiology lab for incubation and quantitative analysis of streptococcus mutans. morphological identification of the bacterial colonies was then confirmed using matrix assisted laser desorption/ionization time of flight (maldi-tof) mass spectrometry.

Eligibility criteria:
inclusion criteria: * patients presenting to the dental clinic for routine dental treatment (including recall exams, new patient exams, and operative appointments) who are american society of anesthesia (asa) class i or ii * cooperative patients classified as 3 or 4 according to the frankl behavioral rating scale, * no known allergies or sensitivities to products or ingredients being tested * had untreated cavities * nothing to eat/drink for 1 hour prior to dental appointment exclusion criteria: * patients who are asa class iii, iv, v or vi * known allergies or sensitivities to any of the mouth rinses or any of the ingredients in the mouth rinses to be tested * non-english speaking parent/participant * patient presenting to the clinic as a walk in or emergency appointment * patient experiencing any pain or sensitivity * precooperative or uncooperative behavior or behavior classified as 1 or 2 according to the frankl behavioral rating scale

Keywords: streptococcus mutans saliva
automated breast ultrasound screening

Conditions: Breast Cancer

Summary: women with dense breasts (birads 3 or 4) with a birads category 1 or 2 mammogram are asked to participate in a automated volume breast ultrasound scanner. the study evaluates prospectively the changes in recall rate, positive biopsy rate, cancer detection rate when birads category 3 lesions are given a 1 year follow-up recommendation.

women with dense breasts (birads 3 or 4) with a birads category 1 or 2 mammogram are asked to participate in a automated volume breast ultrasound scanner. if the women agrees to participate and sign informed consent she undergoes an automated whole breast scan. the scan is interpreted independent of the mammogram. scans are assigned a birads category score of 1, 2, 3,or 0. birads category 3 lesions are reported as no evidence of malignancy and a 1 year follow-up is recommended. birads category 0 lesions are requested to have a hand held ultrasound including elastography. follow up is then determined by birads score and elastography results of hand held ultrasound. the study evaluates prospectively the changes in recall rate, positive biopsy rate, cancer detection rate when birads category 3 lesions are given a 1 year follow-up recommendation.

Eligibility criteria:
inclusion criteria: * women age \>18 scheduled for routine screening mammogram. women with density 3 or 4 and birads category 1 or mammogram are asked to participate in study exclusion criteria: * inability to give informed consent

Keywords: breast cancer automated whole breast ultrasound bi-rads category 3 lesions
a comparison of conventional adult out-of-hospital cardiopulmonary resuscitation against a concept with mechanical chest compressions and simultaneous defibrillation - linc study

Conditions: Cardiovascular Diseases

Summary: the primary objective is to show superiority in survival of the modified method with the lucas chest compression system, compared to the conventional manual resuscitation method in patients suffering from out of hospital sudden cardiac arrest.

every year 300 000 to 400 000 people suffer from sudden cardiac arrest outside of the hospital in europe. only 5 - 7 % of these patients survive and are discharged from hospital. in spite of massive education, research and new methods the survival rate has not improved. in the latest international guidelines for cpr, published in 2005, there is a strong emphasis on chest compressions with as little interruptions as possible. manual chest compressions during cpr result in only 20-30% of normal blood flow and are difficult to perform for a long period of time. mechanical chest compressions with the lucas device have shown increased blood flow in experimental studies. defibrillation during ongoing mechanical compressions is a new method of treatment that showed promising results in increased short time survival in out of hospital cardiac arrest in a recently completed pilot study. the linc trial is a prospective randomised multicenter study where lucas according to a concept will be used with simultaneous defibrillation compared to manual chest compressions according to 2005 guidelines for advanced cpr. the study will be conducted in first tier systems, where lucas always will be placed in the first arriving ambulance.

Eligibility criteria:
inclusion criteria: * unexpected adult out-of-hospital cardiac arrest where an attempt of resuscitation is considered appropriate. exclusion criteria: * traumatic cardiac arrest, including hanging * age believed to be less than 18 years (no upper limit) * known pregnancy * defibrillated before lucas chest compressions system arrives at scene * patients body size not fitting the lucas chest compression system

Keywords: cpr mechanical manual survival rosc